Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 330 clinical trials
A Phase 1 Study of HLX20 a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

This is an open-label, dose escalation, first-in-human study of HLX20, an anti-PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed standard therapy.

  • 22 Jan, 2021
  • 5 locations
Phase I Tolerability Efficacy and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.

  • 26 Jan, 2021
  • 1 location
Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma

Combination of anti-angiogenic molecular targeted therapy and anti- programmed cell death -1 immune checkpoint inhibitor (ICI) therapy has shown promising antitumor activity in multiple cancer types, including patients with advanced hepatocellular carcinoma (HCC). The safety profile and optimal dosage of targeted therapy should be carefully evaluated by clinical trials. Regorafenib …

  • 28 Jan, 2021
  • 1 location
A Phase II Study of Tegafur/Uracil (UFUR )Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Primary objective: To evaluate the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma. Secondary objectives: 1. To determine the disease stabilization rate; 2. To assess the progression-free survival and overall survival; 3. To establish the safety profile; 4. To evaluate the …

ct scan
measurable disease
radiofrequency ablation
arterial embolization
local therapy
  • 07 Nov, 2020
  • 1 location
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in …

  • 23 Jan, 2021
  • 6 locations
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

This is an open label, prospective, trial that begins with a phase Ib safety run-in followed by a phase II expansion cohort.

prostate adenocarcinoma
gilbert's syndrome
neutrophil count
bone metastases
  • 26 Jan, 2021
  • 1 location
A Counter Measure for the Effects of Immune and Microbiome Changes in Environments With Limited ANtigen Diversity (ICELAND-TWO)

There is evidence to indicate that the gut microbiota has an effect on mental well-being and stress behaviours. This is highly relevant to both life on earth and spaceflight missions, in which mental well-being is crucial to mission success. Bifidobacterium longum 1714 (BL 1714), will be tested in the project …

  • 22 Jan, 2021
  • 1 location
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

(IIT) of Nivolumab (BMS-936558) combined with Ipilimumab vs standard of care in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma (nccRCC

measurable disease
clear cell renal cell carcinoma
  • 25 Jan, 2021
  • 41 locations
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal Gastroesophageal and Renal Cancers

therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.

measurable disease
kidney cancer
metastatic colorectal cancer
  • 03 Mar, 2021
  • 40 locations
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer The PDIGREE Study

cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body. The addition of cabozantinib to the usual treatment may make it work better. Immunotherapy with

programmed cell death 1 ligand 1
karnofsky performance status
liver metastasis
measurable disease
  • 01 Mar, 2021
  • 653 locations